Strasbourg Cedex

• DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together w … Ended recruitment
  2023-506007-26-00 3 2024-01-15 relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)
• DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small … Ended recruitment
  2023-506008-20-00 3 2024-01-11 Extensive-stage small cell lung carcinoma (ES-SCLC)
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended recruitment
  2022-502669-14-00 5 2023-12-18 Small cell lung cancer (SCLC)
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended recruitment
  2024-510627-20-00 5 2023-07-28 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
• A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended recruitment
  2022-501352-28-00 5 2023-06-07 Severe community-acquired pneumonia (sCAP)
• TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis. Ended recruitment
  2022-501027-25-01 11 2023-06-01 Multiple Sclerosis
• IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre … Ended recruitment
  2022-502103-30-00 4 2023-04-25 advanced non-squamous non-small cell lung cancer
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended recruitment
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c … Ended recruitment
  2024-511169-12-00 5 2023-03-28 Non-Small Cell Lung Cancer
• PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien … Ended recruitment
  2022-501217-31-00 10 2023-03-09 Hepatocellular carcinoma
• An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended recruitment
  2023-510081-27-00 9 2023-02-28 Systemic Lupus Erythematosus.
• Efficacy and Safety Study of Nipocalimab for Adults with Active Inflammatory Myopathies Ended recruitment
  2023-505314-20-00 4 2023-01-20 Active Idiopathic Inflammatory Myopathies (IIM)
• PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended recruitment
  2023-505057-40-00 4 2022-12-02 Lung Cancer, Non-Small Cell
• Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-N … Ended recruitment
  2024-515845-40-00 5 2022-11-22 Acute kidney injury
• A global study to evaluate transarterial chemoembolization(TACE) in combination with durvalumab, tremelimumab +/-lenvatinib therapy compared … Ended recruitment
  2023-508701-24-00 5 2022-11-21 Locoregional Hepatocellular Carcinoma (HCC)
• RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane … Ended recruitment
  2024-516168-27-00 5 2022-11-10 Adult patients with persistent or chronic immune thrombocytopenia
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Ended recruitment
  2023-510387-13-00 4 2022-05-18 advanced ALK-positive non-small cell lung cancer
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended recruitment
  2023-506867-33-01 4 2022-01-25 Chronic Hepatitis B
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma … Ended recruitment
  2024-512634-15-00 9 2022-01-05 Patients with untreated mantle cell lymphoma
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended recruitment
  2023-506518-33-00 5 2021-11-10 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat … Ended recruitment
  2023-507698-16-00 5 2021-10-14 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322
• PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll … Ended recruitment
  2024-511321-54-00 5 2021-08-04 intermediate-high-risk acute pulmonary embolism

Showing 169–192 of 291 trials